Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 104 participants.

Also called NCT05533632

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 104 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05533632
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Chile (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05533632. Allocation not applicable; no masking; primary purpose treatment. Start 2022-04-25 (actual); primary completion 2024-01-18 (actual). Results posted on 2025-02-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Semaglutide
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct05533632
Content hash
cad098f2f38f8678d61ccc2405681a863752c69b2dc16f997916d9100f12a287